Physician

Ayman Barakat, M.D.

According to 2025 Medicare claims, Ayman Barakat, M.D. (NPI: 1134320328) practices medical oncology in the Tampa, FL market, with the plurality of this provider's patient population coming from Hernando, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 34608-1329.

Barakat's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 714 traditional Medicare patients, billed 192,042 HCPCS/CPT codes, and received $3,319,876 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,368 prescription claims across 262 beneficiaries totaling $2,166,261 in drug costs, led by Nubeqa (Darolutamide). 2021 DME data shows 33 claims. Open Payments data shows 127 records totaling $2,568. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $581,509 to $3,319,876. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $186,156 to $2,166,261. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	438	78,944	$581,509
2016	727	83,486	$820,237
2017	745	249,226	$1,885,003
2018	835	316,976	$3,036,955
2019	827	316,371	$4,012,656
2020	738	268,820	$3,465,228
2021	762	303,396	$4,374,846
2022	678	263,138	$3,567,066
2023	750	258,270	$3,821,647
2024	714	192,042	$3,319,876

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	153	440	$186,156
2016	99	224	$148,694
2017	93	410	$231,827
2018	131	754	$856,079
2019	151	954	$691,091
2020	169	1,145	$1,188,099
2021	199	1,422	$1,708,895
2022	200	1,297	$1,715,447
2023	226	1,351	$1,381,623
2024	262	1,368	$2,166,261

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	12	$840
2016	N/R	24	$617
2017	N/R	12	$1,803
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	42	$2,880
2021	N/R	33	$2,562
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	331	1,069	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	179	243	$62
96372	Injection of drug or substance under skin or into muscle	181	696	$10
36415	Insertion of needle into vein for collection of blood sample	546	1,771	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	533	1,852	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Nubeqa	Darolutamide	48	1,440	$486,074
Pomalyst	Pomalidomide	22	616	$366,060
Brukinsa	Zanubrutinib	22	660	$307,539
Ibrance	Palbociclib	11	308	$155,483
Eliquis	Apixaban	120	4,650	$88,539

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	127	$2,568	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ayman Barakat, M.D.?

Tedicare shows public-source Medicare data for Ayman Barakat, M.D. (NPI 1134320328), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ayman Barakat, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ayman Barakat, M.D.?

Ayman Barakat, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Ayman Barakat, M.D. have Open Payments data?

Ayman Barakat, M.D. has 127 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.